TB-500: Molecular Characterization and Actin-Binding Interactions — A Research Reference

Thymosin beta-4 is a 43-residue polypeptide of roughly 4,900 daltons and one of the most abundant members of the beta-thymosin family. Its defining biochemical property is that it binds monomeric actin — the globular form of the cytoskeletal protein — and it was characterized alongside thymosin beta-10 as an actin monomer sequestering protein [1].

The region responsible for that binding has been mapped to a short internal stretch: the heptapeptide leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, written LKKTETQ. It sits in the central portion of the parent sequence and is frequently described as the actin-binding motif. Because it is short, it can be made by standard solid-phase synthesis without the difficulties attaching to a 43-residue chain, and the acetylated form of this fragment weighs approximately 890 daltons.

Beta-thymosins are intrinsically disordered in isolation. They adopt no stable fold on their own and acquire defined secondary structure only upon binding their partner — a property established structurally for the family and central to how the interaction is understood [3]. That behaviour also explains why they remain soluble and well-behaved in solution relative to peptides that aggregate.

The beta-thymosin naming should be separated from the alpha-thymosins. Thymosin alpha-1 is an unrelated 28-residue peptide with a different sequence; the shared word points to a common tissue of origin in the original isolation work rather than to any structural relationship.

Unlike most compounds in this catalogue, the beta-thymosins are not receptor ligands. Their characterized interaction is with a cytoskeletal protein, and the relevant in-vitro pharmacology is protein-protein binding rather than G-protein-coupled receptor activation.

The binding is stoichiometric sequestration: the peptide holds monomeric actin in a complex that prevents its incorporation into filaments, and the family was defined by this activity across multiple members [1]. Structural work on actin-bound beta-thymosin constructs subsequently resolved how the disordered chain organizes upon binding, establishing that the interaction induces structure in the peptide rather than selecting a pre-formed conformation [3].

Comparative studies across beta-thymosin variants — including the sulfoxide form and N-terminally truncated derivatives — established which parts of the sequence are required for binding and how chemical modification of the chain alters the interaction [2]. That work is directly relevant to interpreting a batch whose oxidation state is uncertain, because the sulfoxide is not merely an impurity but a variant with altered binding behaviour.

Mass spectrometry confirms the intact molecular mass and, for this compound in particular, resolves the entity question described above. An observed mass near 890 daltons and one near 4,900 daltons are both entirely consistent with a certificate headed TB-500, and only one corresponds to any given order. The theoretical mass quoted on the certificate is what identifies which was supplied.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. In a short synthetic sequence the common related substances are deletion sequences, where a residue failed to couple. In a 43-residue chain the same failures are more numerous and harder to separate, which is one practical reason the two entities are not equivalent to work with even where both are pure.

Oxidation state warrants specific attention. The full-length sequence contains a methionine, and its sulfoxide is a defined variant with characterized binding differences rather than an inert contaminant [2]. Oxidation adds a defined sixteen-dalton increment, so a batch carrying the sulfoxide shows a satellite mass above the target.

Amino acid analysis appears on some certificates as an orthogonal confirmation of composition, providing a compositional check independent of the mass measurement.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents. Because the two entities differ so greatly in molecular weight, the molar quantity in a nominal 10 mg vial differs by roughly fivefold between them.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided. Solutions are treated as short-lived relative to the lyophilized form.

The heptapeptide fragment contains no cysteine and no methionine, removing two of the more common oxidation routes. The full-length polypeptide does contain a methionine, so an oxidation-sensitive handling regime applies to it and not to the fragment — another respect in which knowing which entity is in the vial changes bench practice. Both sequences contain threonine and glutamine, and glutamine is subject to slow deamidation in solution, a further reason solutions are made up as needed rather than held.

Chain length also governs mechanical handling: a 43-residue chain presents considerably more surface for aggregation under agitation than a seven-residue one, and is handled with correspondingly more care.

TB-500 is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade TB-500 is accompanied by an independent certificate of analysis specific to that lot.

TB-500 is a research code covering two distinct entities: thymosin beta-4, a 43-residue intrinsically disordered actin monomer sequestering polypeptide of roughly 4,900 daltons, and the acetylated heptapeptide LKKTETQ of roughly 890 daltons corresponding to its actin-binding motif. The characterized interaction is protein-protein binding to monomeric actin rather than receptor activation, and structural work established that the peptide acquires order upon binding. Analytical verification rests on mass confirmation of which entity was supplied, chromatographic resolution of deletion sequences, attention to methionine oxidation state where the full-length chain is present, and batch-specific net peptide content.